547 The Phase III trial of olpasiran aims to compare its effects with the placebo on the risk of coronary heart disease death, myocardial infarction, and urgent coronary revascularization in ASCVD patients with elevated Lp(a), with results expected by 2026 (NCT05581303)
"Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)"
Supplementation issuitable for vegetarians, athletes and those wanting to maintain healthy body fat levels
Many users report noticing improvement within the first week, with more substantial gains developing over 4 to 8 weeks of use
And most of these are case reports and observational studies
J Alzheimer's Dis 40:519529 Gu M, Owen AD, Toffa SE, Cooper JM, Dexter DT, Jenner P, Marsden CD, Schapira AH (1998) Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases